2017
DOI: 10.4236/ojmip.2017.71001
|View full text |Cite
|
Sign up to set email alerts
|

The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size

Abstract: Aims: There has been no evidence on the effects of evolocumab, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, on small size LDL. We observationally investigated the efficacy and side effects of evolocumab on the LDL subfraction particle diameter using PAGE system for lipoprotein analysis. Methods: We defined 30 patients with high-risk hyperlipidemia. As for analysis of LDL subfraction profile, we used polyacrylamide gel electrophoresis three methods: 1) 3% nondenatured poly-acrylamide gel electr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 34 publications
(28 reference statements)
0
2
0
Order By: Relevance
“…We used our previous criteria 15 that we describe in detail. Major exclusion criteria were as follows: (1) patients treated with glucagon-like peptide 1 (GLP-1) receptor agonists, (2) CKD (eGFR < 45 mL/min), (3) fasting TG greater than or equal to 400 mg/dL, (4) blood pressure >180/110 mmHg, (5) A1c that changed by more than 2% within 3 months, (6) severe ketosis, diabetic coma or precoma, peripheral artery disease, abdominal aortic aneurysm, carotid artery occlusion >50% without symptoms, carotid endarterectomy, carotid artery stent procedure, renal artery stenosis, or renal artery stent procedure, (7) severe infection before and after surgery, patients determined to be ineligible for the trial by the investigator or a doctor and those suffering from serious trauma, (8) pregnant or breast-feeding women, (9) women of childbearing potential with no effective contraceptive method, (10) participants not previously instructed on a cholesterol-lowering diet in the first visit who were being treated with a stable dose of statins for at least 6 weeks prior to screening.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…We used our previous criteria 15 that we describe in detail. Major exclusion criteria were as follows: (1) patients treated with glucagon-like peptide 1 (GLP-1) receptor agonists, (2) CKD (eGFR < 45 mL/min), (3) fasting TG greater than or equal to 400 mg/dL, (4) blood pressure >180/110 mmHg, (5) A1c that changed by more than 2% within 3 months, (6) severe ketosis, diabetic coma or precoma, peripheral artery disease, abdominal aortic aneurysm, carotid artery occlusion >50% without symptoms, carotid endarterectomy, carotid artery stent procedure, renal artery stenosis, or renal artery stent procedure, (7) severe infection before and after surgery, patients determined to be ineligible for the trial by the investigator or a doctor and those suffering from serious trauma, (8) pregnant or breast-feeding women, (9) women of childbearing potential with no effective contraceptive method, (10) participants not previously instructed on a cholesterol-lowering diet in the first visit who were being treated with a stable dose of statins for at least 6 weeks prior to screening.…”
Section: Methodsmentioning
confidence: 99%
“… 13 , 14 Moreover, the addition of evolocumab to the statin therapy achieved serum LDL-C levels of less than 30 mg/dL. 1 , 15 The effects of PCSK9 inhibitors, which have potent LDL-lowering activities, on vascular calcification have been of attracting interest. However, it currently remains unclear whether PCSK9 inhibitors modulate coronary atheroma calcification in vivo in humans.…”
Section: Introductionmentioning
confidence: 99%